Seeking Alpha

Jazz Pharmaceuticals (JAZZ) receives coverage from Piper Jaffray with an initial rating of...

Jazz Pharmaceuticals (JAZZ) receives coverage from Piper Jaffray with an initial rating of Overweight and a $51 price target. Shares +1.4% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)